NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free MDGL Stock Alerts $205.20 -13.18 (-6.04%) (As of 03:09 PM ET) Add Compare Share Share Today's Range$204.80▼$220.0050-Day Range$212.04▼$283.2352-Week Range$119.76▼$322.67Volume312,929 shsAverage Volume524,281 shsMarket Capitalization$4.08 billionP/E RatioN/ADividend YieldN/APrice Target$356.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Madrigal Pharmaceuticals alerts: Email Address Madrigal Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside73.8% Upside$356.73 Price TargetShort InterestBearish16.88% of Shares Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.70Based on 7 Articles This WeekInsider TradingSelling Shares$31.36 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($21.48) to ($13.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector77th out of 909 stocksPharmaceutical Preparations Industry25th out of 423 stocks 4.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.88% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 3.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 3.2 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 27 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows25 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 4% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,362,420.00 in company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($21.48) to ($13.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 10.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesApril 11, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 SharesApril 11, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of StockApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 9, 2024 | insidertrades.comJames M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockApril 6, 2024 | insidertrades.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 18,710 Shares of StockApril 4, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Richard S. Levy Sells 11,000 SharesMarch 28, 2024 | marketbeat.com7 Stocks That Will Drive the Weight Loss Drugs Market (MDGL)The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.April 23, 2024 | finance.yahoo.comMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 23, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Coverage Initiated by Analysts at Bank of AmericaApril 22, 2024 | markets.businessinsider.comUnited Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy RatingApril 20, 2024 | msn.comMadrigal Pharmaceuticals Welcomes New Employees with Equity AwardsApril 16, 2024 | globenewswire.comMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 15, 2024 | investorplace.com7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024April 10, 2024 | msn.comMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH TreatmentApril 10, 2024 | msn.com2 Under-the-Radar Growth Stocks to ConsiderApril 10, 2024 | fool.com2 Under-the-Radar Growth Stocks to ConsiderApril 9, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisApril 7, 2024 | cnn.comMadrigal Pharmaceuticals, Inc.April 6, 2024 | msn.comMadrigal Pharmaceuticals Awards Equity to New Employees as InducementApril 5, 2024 | fool.comBetter Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking TherapeuticsApril 4, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 SharesApril 4, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 SharesApril 4, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc Director James Daly Sells 32,489 SharesApril 3, 2024 | globenewswire.comMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | fool.com1 No-Brainer Growth Stock to Buy NowApril 2, 2024 | seekingalpha.comViking Therapeutics: Future Weight Loss Heavyweight?See More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees376Year Founded2011Price Target and Rating Average Stock Price Target$356.73 High Stock Price Target$425.00 Low Stock Price Target$150.00 Potential Upside/Downside+63.4%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($19.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-219.39% Return on Assets-98.75% Debt Debt-to-Equity Ratio0.28 Current Ratio5.38 Quick Ratio5.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book10.64Miscellaneous Outstanding Shares19,900,000Free Float15,138,000Market Cap$4.35 billion OptionableOptionable Beta-0.47 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Comp: $939.83kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Comp: $763.75kMr. Alex G. Howarth (Age 55)Executive Officer Comp: $757.26kMr. William J. Sibold (Age 58)CEO, President & Director Ms. Mardi C. Dier (Age 60)CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical OperationsMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDDicerna PharmaceuticalsNASDAQ:DRNAIonis PharmaceuticalsNASDAQ:IONSRocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 6,124 shares on 4/24/2024Ownership: 0.065%Sweet Financial Partners LLCBought 1,000 shares on 4/23/2024Ownership: 0.005%Raymond James & AssociatesBought 554 shares on 4/22/2024Ownership: 0.102%Shikiar Asset Management Inc.Bought 400 shares on 4/22/2024Ownership: 0.027%PFG Investments LLCBought 858 shares on 4/22/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions MDGL Stock Analysis - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price target for 2024? 11 brokers have issued 12-month price targets for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $150.00 to $425.00. On average, they expect the company's share price to reach $356.73 in the next year. This suggests a possible upside of 73.8% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2024? Madrigal Pharmaceuticals' stock was trading at $231.38 on January 1st, 2024. Since then, MDGL stock has decreased by 11.3% and is now trading at $205.20. View the best growth stocks for 2024 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our MDGL earnings forecast. How can I listen to Madrigal Pharmaceuticals' earnings call? Madrigal Pharmaceuticals will be holding an earnings conference call on Tuesday, May 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by $0.42. During the same quarter in the prior year, the business posted ($4.98) earnings per share. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Tema Cardiovascular and Metabolics ETF (HRTS), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Rheos Capital Works Inc. (0.55%), Hennion & Walsh Asset Management Inc. (0.16%), Raymond James & Associates (0.10%), Assenagon Asset Management S.A. (0.07%), AMI Asset Management Corp (0.05%) and Shikiar Asset Management Inc. (0.03%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy and Robert E Waltermire. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDGL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
